Literature DB >> 8124056

Inhibition of superoxide anion release from circulating neutrophils by L-arginine in man.

C J Wiedermann1, B Sitte, U Zilian, N Reinisch, H Beimpold, G Finkenstedt, H Braunsteiner.   

Abstract

In animal studies of myocardial ischemia/reperfusion L-arginine reduces necrotic injury by preservation of endothelial function and attenuation of neutrophil accumulation in ischemic cardiac tissue. Because release of oxygen radical species by circulating neutrophils is important in endothelial function and ischemia-reperfusion injury, this study investigated the effect of intravenous administration of L-arginine on the in vitro release of superoxide anion of neutrophils in healthy young adults. Neutrophils were obtained at various time points before, during, and after infusion of L-arginine (17 mg kg-1 min-1 for 30 min) and analyzed for superoxide dismutase inhibitable reduction of ferricytochrome c. The spontaneously occurring respiratory burst of polymorphonuclear leukocytes at basal conditions was compared with that after triggering by 1 mumol/l formylpeptide or 50 ng/ml phorbolester. Infusion of L-arginine inhibited both basal (P < 0.01) and formylpeptide-triggered (P < 0.05) release of superoxide anion did, but not affect release stimulated by phorbol 12-myristate 13-acetate. Pretreatment of neutrophils with 1 mmol/l L-arginine in vitro also significantly reduced formylpeptide-triggered (1 mumol/l) superoxide anion release, suggesting that the affects observed after in vivo pretreatment may be due to direct action of L-arginine on neutrophils. These findings demonstrate the ability of L-arginine to reduce release of oxygen radical species by circulating neutrophils in man.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8124056     DOI: 10.1007/bf00180028

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  16 in total

Review 1.  Nitric oxide: physiology, pathophysiology, and pharmacology.

Authors:  S Moncada; R M Palmer; E A Higgs
Journal:  Pharmacol Rev       Date:  1991-06       Impact factor: 25.468

2.  L-arginine-induced hypotension.

Authors:  T Nakaki; K Hishikawa; H Suzuki; T Saruta; R Kato
Journal:  Lancet       Date:  1990-09-15       Impact factor: 79.321

3.  In vivo EDRF activity influences platelet function.

Authors:  J C Hogan; M J Lewis; A H Henderson
Journal:  Br J Pharmacol       Date:  1988-08       Impact factor: 8.739

4.  Inhibition of nitric oxide synthesis in septic shock: how much is beneficial?

Authors:  E Nava; R M Palmer; S Moncada
Journal:  Lancet       Date:  1991 Dec 21-28       Impact factor: 79.321

5.  Phorbol diester receptor copurifies with protein kinase C.

Authors:  J E Niedel; L J Kuhn; G R Vandenbark
Journal:  Proc Natl Acad Sci U S A       Date:  1983-01       Impact factor: 11.205

6.  Cyclic GMP mediates SIN-1-induced inhibition of human polymorphonuclear leukocytes.

Authors:  H Schröder; P Ney; I Woditsch; K Schrör
Journal:  Eur J Pharmacol       Date:  1990-07-03       Impact factor: 4.432

7.  Synthesis of nitric oxide from L-arginine by neutrophils. Release and interaction with superoxide anion.

Authors:  T B McCall; N K Boughton-Smith; R M Palmer; B J Whittle; S Moncada
Journal:  Biochem J       Date:  1989-07-01       Impact factor: 3.857

8.  Endothelium-derived relaxing factor inhibits platelet aggregation in human whole blood in vitro and in the rat in vivo.

Authors:  R Bhardwaj; C P Page; G R May; P K Moore
Journal:  Eur J Pharmacol       Date:  1988-11-15       Impact factor: 4.432

9.  The role of nitric oxide as an endogenous regulator of platelet and neutrophil activation within the pulmonary circulation of the rabbit.

Authors:  G R May; P Crook; P K Moore; C P Page
Journal:  Br J Pharmacol       Date:  1991-03       Impact factor: 8.739

10.  Regulation of macrophage functions by L-arginine.

Authors:  J E Albina; M D Caldwell; W L Henry; C D Mills
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

View more
  3 in total

1.  Superoxide anion release from neutrophils in growth hormone deficient adults before and after replacement therapy with recombinant human growth hormone.

Authors:  N Reinisch; P Schratzberger; G Finkenstedt; C M Kähler; C J Wiedermann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996 Aug-Sep       Impact factor: 3.000

2.  Nitric oxide and octreotide in retinal ischemia-reperfusion injury.

Authors:  Ulku Celiker; Necip Ilhan
Journal:  Doc Ophthalmol       Date:  2002-11       Impact factor: 2.379

3.  Effect of nitric oxide on staphylococcal killing and interactive effect with superoxide.

Authors:  S S Kaplan; J R Lancaster; R E Basford; R L Simmons
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.